Literature DB >> 12668802

Nuclear localisation of p65 in sputum macrophages but not in sputum neutrophils during COPD exacerbations.

G Caramori1, M Romagnoli, P Casolari, C Bellettato, G Casoni, P Boschetto, K F Chung, P J Barnes, I M Adcock, A Ciaccia, L M Fabbri, A Papi.   

Abstract

BACKGROUND: Exacerbations represent an important feature of the clinical manifestation and natural history of chronic obstructive pulmonary disease (COPD). Nuclear localisation of p65 is a signal of nuclear factor-kappaB (NF-kappaB) activation. A study was undertaken to evaluate whether NF-kappaB activation is modified in sputum cells during COPD exacerbations.
METHODS: Total and nuclear p65 immunoreactivity was measured by immunocytochemistry in the sputum cells of 11 smokers with moderate COPD during an exacerbation and after 6-8 weeks of clinical stability.
RESULTS: Total sputum cell count was significantly increased during exacerbations from a median (IQR) of 880 (510-1865) to 1914.5 (1065-3205) x 10(3)/ml (p<0.05). The main inflammatory cells in the sputum were neutrophils (83.2 (75.4-92.3)%) and macrophages (14.7 (2.6-21.6)%) and their relative proportion did not change during exacerbations. Nuclear staining for p65 was absent in sputum neutrophils, both during exacerbations and in the stable phase. In contrast, the percentage of macrophages expressing nuclear p65 increased significantly during exacerbations from a median (IQR) of 16 (7-24)% to 41.4 (6-69)% (p<0.05).
CONCLUSIONS: NF-kappaB appears to be activated in sputum macrophages but not in sputum neutrophils during exacerbations of COPD

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12668802      PMCID: PMC1746629          DOI: 10.1136/thorax.58.4.348

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  9 in total

1.  Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease.

Authors:  A Papi; M Romagnoli; S Baraldo; F Braccioni; I Guzzinati; M Saetta; A Ciaccia; L M Fabbri
Journal:  Am J Respir Crit Care Med       Date:  2000-11       Impact factor: 21.405

Review 2.  Chronic obstructive pulmonary disease.

Authors:  P J Barnes
Journal:  N Engl J Med       Date:  2000-07-27       Impact factor: 91.245

Review 3.  Cellular and structural bases of chronic obstructive pulmonary disease.

Authors:  M Saetta; G Turato; P Maestrelli; C E Mapp; L M Fabbri
Journal:  Am J Respir Crit Care Med       Date:  2001-05       Impact factor: 21.405

4.  Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations.

Authors:  A Bhowmik; T A Seemungal; R J Sapsford; J A Wedzicha
Journal:  Thorax       Date:  2000-02       Impact factor: 9.139

Review 5.  Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases.

Authors:  P J Barnes; M Karin
Journal:  N Engl J Med       Date:  1997-04-10       Impact factor: 91.245

6.  Lipopolysaccharide-induced NF-kappaB activation and cytokine release in human alveolar macrophages is PKC-independent and TK- and PC-PLC-dependent.

Authors:  A B Carter; M M Monick; G W Hunninghake
Journal:  Am J Respir Cell Mol Biol       Date:  1998-03       Impact factor: 6.914

7.  Activation of the NF-kappaB pathway by inflammatory stimuli in human neutrophils.

Authors:  P P McDonald; A Bald; M A Cassatella
Journal:  Blood       Date:  1997-05-01       Impact factor: 22.113

8.  IL-5, IL-8 and GM-CSF immunostaining of sputum cells in bronchial asthma and chronic bronchitis.

Authors:  H Hoshi; I Ohno; M Honma; Y Tanno; K Yamauchi; G Tamura; K Shirato
Journal:  Clin Exp Allergy       Date:  1995-08       Impact factor: 5.018

9.  New strains of bacteria and exacerbations of chronic obstructive pulmonary disease.

Authors:  Sanjay Sethi; Nancy Evans; Brydon J B Grant; Timothy F Murphy
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

  9 in total
  57 in total

1.  Inhaled LPS challenges in smokers: a study of pulmonary and systemic effects.

Authors:  Raminder Aul; Jane Armstrong; Annelyse Duvoix; David Lomas; Brian Hayes; Bruce E Miller; Chris Jagger; Dave Singh
Journal:  Br J Clin Pharmacol       Date:  2012-12       Impact factor: 4.335

2.  Opposing effects of bortezomib-induced nuclear factor-κB inhibition on chemical lung carcinogenesis.

Authors:  Sophia P Karabela; Ioannis Psallidas; Taylor P Sherrill; Chrysoula A Kairi; Rinat Zaynagetdinov; Dong-Sheng Cheng; Spyridoula Vassiliou; Frank McMahon; Linda A Gleaves; Wei Han; Ioannis Stathopoulos; Spyros G Zakynthinos; Fiona E Yull; Charis Roussos; Ioannis Kalomenidis; Timothy S Blackwell; Georgios T Stathopoulos
Journal:  Carcinogenesis       Date:  2012-01-27       Impact factor: 4.944

Review 3.  Pathogenesis of chronic obstructive pulmonary disease.

Authors:  William MacNee
Journal:  Proc Am Thorac Soc       Date:  2005

4.  NF-κB activation is required for the transition of pulmonary inflammation to muscle atrophy.

Authors:  Ramon C J Langen; Astrid Haegens; Juanita H J Vernooy; Emiel F M Wouters; Menno P J de Winther; Harald Carlsen; Chad Steele; Steven E Shoelson; Annemie M W J Schols
Journal:  Am J Respir Cell Mol Biol       Date:  2012-04-26       Impact factor: 6.914

5.  Genome-Wide Association Study of the Genetic Determinants of Emphysema Distribution.

Authors:  Adel Boueiz; Sharon M Lutz; Michael H Cho; Craig P Hersh; Russell P Bowler; George R Washko; Eitan Halper-Stromberg; Per Bakke; Amund Gulsvik; Nan M Laird; Terri H Beaty; Harvey O Coxson; James D Crapo; Edwin K Silverman; Peter J Castaldi; Dawn L DeMeo
Journal:  Am J Respir Crit Care Med       Date:  2017-03-15       Impact factor: 21.405

6.  Chronic obstructive pulmonary disease: an update of treatment related to frequently associated comorbidities.

Authors:  Nicola J Sinden; Robert A Stockley
Journal:  Ther Adv Chronic Dis       Date:  2010-03       Impact factor: 5.091

7.  Anti-inflammatory effect of a selective IkappaB kinase-beta inhibitor in rat lung in response to LPS and cigarette smoke.

Authors:  Saravanan Rajendrasozhan; Jae-Woong Hwang; Hongwei Yao; Nandini Kishore; Irfan Rahman
Journal:  Pulm Pharmacol Ther       Date:  2010-01-18       Impact factor: 3.410

8.  Effects of intratracheal administration of nuclear factor-kappaB decoy oligodeoxynucleotides on long-term cigarette smoke-induced lung inflammation and pathology in mice.

Authors:  Yu-Tao Li; Bei He; Yu-Zhu Wang; Jing Wang
Journal:  Respir Res       Date:  2009-08-25

Review 9.  Antioxidant therapies in COPD.

Authors:  Irfan Rahman
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

Review 10.  Biological targets for therapeutic interventions in COPD: clinical potential.

Authors:  Girolamo Pelaia; Alessandro Vatrella; Luca Gallelli; Teresa Renda; Mario Caputi; Rosario Maselli; Serafino A Marsico
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.